COVID-19 Serological Study in Non-infected Vaccinated Subjects: Differences among Age, Sex, and Vaccine Brand.

Puerto Rico health sciences journal Pub Date : 2023-09-01

Yaniré Castro-Torres, Estela S Estapé, María T San Martín, Deana Hallman

{"title":"COVID-19 Serological Study in Non-infected Vaccinated Subjects: Differences among Age, Sex, and Vaccine Brand.","authors":"Yaniré Castro-Torres, Estela S Estapé, María T San Martín, Deana Hallman","doi":"","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate IgG antibody levels against SARS-CoV-2 in non-infected vaccinated subjects among vaccine brand, sex, and age.Methods: Abbott's AdviseDx SARS-CoV-2 IgG II immunoassay was used to measure IgG levels within 6-9 months after the second dose vaccination; level >50 AU/mL was classified as a positive test.Results: Data of 183 non-infected vaccinated subjects was analyzed according to the vaccine brand, time after second vaccination, sex, and age. Bivariate analysis showed that receiving the Moderna brand vaccine, being female, and younger were associated with higher antibody levels, p<.001. Conversely, no differences were observed between the IgG antibody levels against SARS-CoV-2 and time after second vaccination (6-7 months as compared to 8-9 months), p=.49.Conclusion: After six to nine months post-vaccination, receiving the Moderna vaccine, being female, and being younger were significantly associated to higher IgG antibody levels to SARS-CoV-2 in non-infected vaccinated subjects.","PeriodicalId":94183,"journal":{"name":"Puerto Rico health sciences journal","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11302121/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Puerto Rico health sciences journal","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To evaluate IgG antibody levels against SARS-CoV-2 in non-infected vaccinated subjects among vaccine brand, sex, and age.

Methods: Abbott's AdviseDx SARS-CoV-2 IgG II immunoassay was used to measure IgG levels within 6-9 months after the second dose vaccination; level >50 AU/mL was classified as a positive test.

Results: Data of 183 non-infected vaccinated subjects was analyzed according to the vaccine brand, time after second vaccination, sex, and age. Bivariate analysis showed that receiving the Moderna brand vaccine, being female, and younger were associated with higher antibody levels, p<.001. Conversely, no differences were observed between the IgG antibody levels against SARS-CoV-2 and time after second vaccination (6-7 months as compared to 8-9 months), p=.49.

Conclusion: After six to nine months post-vaccination, receiving the Moderna vaccine, being female, and being younger were significantly associated to higher IgG antibody levels to SARS-CoV-2 in non-infected vaccinated subjects.

本刊更多论文

未感染疫苗受试者的新冠肺炎血清学研究：年龄、性别和疫苗品牌的差异。

目的：评估不同品牌、性别和年龄的未感染疫苗接种者的抗严重急性呼吸系统综合征冠状病毒2型IgG抗体水平。方法：采用Abbott’s AdviseDx SARS-CoV-2 IgG II免疫测定法测定第二剂疫苗接种后6-9个月内的IgG水平；水平＞50 AU/mL被归类为阳性检测。结果：根据疫苗品牌、第二次接种后的时间、性别和年龄，对183名未感染疫苗的受试者的数据进行分析。双变量分析显示，接种莫德纳品牌疫苗的女性和更年轻的人与更高的抗体水平相关，P结论：在接种疫苗后6至9个月后，在未感染的接种受试者中，接种莫rna疫苗的女性、更年轻的人群与较高的严重急性呼吸系统综合征冠状病毒2型IgG抗体水平显著相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Puerto Rico health sciences journal

自引率

0.00%

发文量